MACROGENICS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MACROGENICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $149.50M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $149.96M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $58.75M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $151.94M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $77.45M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $104.88M | Mar 15, 2023 |
| FY2019 | Dec 31, 2019 | $25.19M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $18.74M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $10.59M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $9.66M | Feb 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($74.62M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($66.97M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | ($9.06M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($119.76M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | ($202.12M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | ($129.74M) | Mar 15, 2023 |
| FY2019 | Dec 31, 2019 | ($30.40M) | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | ($44.63M) | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | ($31.77M) | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | ($45.02M) | Feb 25, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($72.84M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($110.58M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | ($168.24M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($121.42M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | ($202.80M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | ($131.06M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | ($177.19M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($171.21M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($22.14M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($60.04M) | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $147.17M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $177.19M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $166.58M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $207.03M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $214.58M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $193.20M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $195.31M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $190.83M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $147.23M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $122.09M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($81.04M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($68.37M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | ($78.21M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($86.96M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | ($143.83M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | ($111.90M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | ($134.27M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($153.23M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $14.41M | Feb 25, 2020 |
| FY2013 | Dec 31, 2013 | ($14.17M) | Mar 20, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.91M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $3.71M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $1.76M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $3.62M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $6.20M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $5.91M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $4.29M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $24.95M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $29.40M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $11.38M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $256.85M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $261.66M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $298.42M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $280.47M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $335.25M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $378.74M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $312.50M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $332.13M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $373.88M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $311.26M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.26M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $145.60M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $145.81M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $138.46M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $95.63M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $82.86M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $81.87M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $89.25M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $74.65M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $42.51M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.59M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $116.06M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $152.61M | Mar 9, 2026 |
| FY2025 | Dec 31, 2022 | $142.01M | Mar 9, 2026 |
| FY2024 | Dec 31, 2021 | $239.62M | Mar 20, 2025 |
| FY2023 | Dec 31, 2020 | $295.88M | Mar 7, 2024 |
| FY2022 | Dec 31, 2019 | $230.63M | Mar 15, 2023 |
| FY2021 | Dec 31, 2018 | $242.88M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $299.24M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $268.75M | Feb 25, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.24B) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($1.17B) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($1.10B) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($1.09B) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($973.94M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($771.82M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($642.08M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($490.27M) | Feb 25, 2020 |
| FY2018 | Jan 1, 2018 | ($318.82M) | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | ($312.34M) | Feb 26, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.22M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $182.84M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $100.96M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $108.88M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $123.47M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $181.13M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $126.47M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $220.13M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $211.73M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $84.10M | Feb 26, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 15, 2023 |
| FY2018 | Dec 31, 2017 | 2 | Feb 26, 2019 |
| FY2018 | Sep 30, 2017 | (1) | Feb 26, 2019 |
| FY2018 | Jun 30, 2017 | (1) | Feb 26, 2019 |
| FY2018 | Mar 31, 2017 | (1) | Feb 26, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 15, 2023 |
| FY2018 | Dec 31, 2017 | 2 | Feb 26, 2019 |
| FY2018 | Sep 30, 2017 | (1) | Feb 26, 2019 |
| FY2018 | Jun 30, 2017 | (1) | Feb 26, 2019 |
| FY2018 | Mar 31, 2017 | (1) | Feb 26, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 63.32M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 62.82M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 62.07M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 61.70M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 61.31M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 56.24M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 48.96M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 42.35M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 36.86M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 34.87M | Feb 27, 2018 |